STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (fg-29)	LONCASTUXIMAB TESIRINE
PRONUNCIATION	lon” kas tux’ i mab tes’ ir een
THERAPEUTIC CLAIM	Treatment of hematological cancers

CHEMICAL NAMES

1. Immunoglobulin G1, (*anti*-human CD19 (antigen)) (humanized clone RB4v1.2 γ1-chain), disulfide with humanized clone RB4v1.2 κ-chain, dimer, bis(thioether) with *N*-[31-(2,5-dihydro-2,5-dioxo-1*H*-pyrrol-1-yl)-1,29-dioxo-4,7,10,13,16,19,22,25-octaoxa-28-azahentriacont-1-yl]-L-valyl-*N*-[4-[[[[(11*S*,11a*S*)-8-[[5-[[(11a*S*)-5,11a-dihydro-7-methoxy-2-methyl-5-oxo-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-8-yl]oxy]pentyl]oxy]-11,11a-dihydro-11-hydroxy-7-methoxy-2-methyl-5-oxo-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-10(5*H*)-yl]carbonyl]oxy]methyl]phenyl]-L-alaninamide

2. Immunoglobulin G1-kappa, anti-(*homo sapiens* B-lymphocyte antigen CD-19); chimeric monoclonal antibody conjugated to an average of two molecules of tesirine; γ1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-69*02 (86%) – (IGHD)-IGHJ4*01)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 {[R^{97}]CH1(K>R(217)),des-K^{107}CH3(K>-(250))}, (121-249)] (223-211')-disulfide with κ light chain (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91%) – IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01 (105'-211')], dimer (229-229'':232-232'')-bisdisulfide, an average of two cysteines are *S*-linked to (1^{11a}*S*,9^{11}*S*,9^{11a}*S*,16*S*,19*S*,52^{3}*RS*)-9^{11}-hydroxy-1^{7}, 9^{7}-dimethoxy-1^{2},9^{2},16-trimethyl-1^{5},9^{5},10,15,18,21,49,52^{2}-52^{5}-nonaoxo-19-(propan-2-yl)-1^{5},1^{11a},9^{11},9^{11a}-tetrahydro-1^{1}*H*,9^{1}*H*,9^{5}*H*-2,8,11,24,27,30,33,36,39,42,45-undecaoxa-14,17,20,48-tetraaza-1(8),9(8,10)-bis(pyrrolo[2,1-*c*][1,4]benzodiazepine)-52(1)-pyrrolidina-13(1,4)benzenadopentacontaphan-52^{3}-yl

STRUCTURAL FORMULA

Heavy chain

QVQLVQPGAE	VVKPGASVKL	SCKTSGYTFT	SNWMHWVKQA	PGQGLEWIGE	50
IDPSDSYTNY	NQNFQGKAKL	TVDKSTSTAY	MEVSSLRSDD	TAVYYCARGS	100
NPYYYAMDYW	GQGTSVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDKKVEP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTCVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTPPV	400
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPG	449

Light chain

EIVLTQSPAI	MSASPGERVT	MTCSASSGVN	YMHWYQQKPG	TSPRRWIYDT	50'
SKLASGVPAR	FSGSGSGTSY	SLTISSMEPE	DAATYYCHQR	GSYTFGGGTK	100'
LEIKRTVAAP	SVFIFPPSDE	QLKSGTASVV	CLLNNFYPRE	AKVQWKVDNA	150'
LQSGNSQESV	TEQDSKDSTY	SLSSTLTLSK	ADYEKHKVYA	CEVTHQGLSS	200'
PVTKSFNRGE	C				211'

Disulfide bridges

22-96	22"-96"	23'-87'	23'"-87'"	131'-191'	131'"-191'"	147-203	147"-203"
211'-223*	211'"-223"*	229-229"*	232-232"*	264-324	264"-324"	370-428	370"-428"

* one or two of the inter-chain disulfide bridges are not present, an average of two Cysteines are *S*-substituted with tesirine C.

Modified residues (C)



Glycosylation sites (N)

Asn-300 Asn-300"

MOLECULAR FORMULA	$C_{6544}H_{10048}N_{1718}O_{2064}S_{52}$
MOLECULAR WEIGHT	147.5 kDa (protein)
TRADEMARK	None as yet
SPONSOR	ADC Therapeutics SA
CODE DESIGNATIONS	ADCT-402
CAS REGISTRY NUMBER	1879918-31-6
UNII	7K5O7P6QIU
WHO NUMBER	10586

gbk